IQ Corporation Announces Key Milestone in Development of Anthrax Monoclonal Antibody Treatments.

GRONINGEN, Netherlands -- Dutch biopharmaceutical company IQ Corporation (IQ) announces the successful completion of PER.C6(R) clone generation for the production of its two fully human monoclonal antibodies against the anthrax lethal toxin components Lethal Factor and Protective Antigen. The clone generation programs were conducted by Invitrogen's (Nasdaq:IVGN) PD-Direct(TM) services for IQ under a licensing agreement with Crucell N.V. and DSM.

"We are very excited about the successful achievement of our clone generation objectives. It enables IQ to advance its unique strategy of the combined application of two different monoclonal antibodies for the treatment of anthrax. Invitrogen's expertise in cell line development and knowledge of the PER.C6(R) platform was a tremendous asset in the timely completion of this important milestone," said Dr. Herman Groen, Chief Scientific Officer at IQ.

"We are very pleased to have the opportunity to contribute to IQ's product development. The PER.C6 clone generation program is a good example of the value that Invitrogen can bring to clients through our PD-Direct services," noted Chris Linthwaite, General Manager for Invitrogen PD-Direct services.

About IQ Corporation

IQ Corporation is a life sciences company based in the Netherlands. Its mission is to contribute to human healthcare through the development and worldwide commercialization of products for diagnostic and therapeutic applications. The company's therapeutics division (IQ Therapeutics) is applying its Cloning the Human Response(TM) technology for its own pipeline and third parties' to generate and develop fully human antibodies from immunized or vaccinated donors for the prevention and treatment of infectious diseases. The company's diagnostic products division (IQ Products) has developed a range of products for flow-cytometry and for perinatal and transplantation related diagnosis, which are sold in more than 50 countries. For more information, please visit www.iqcorporation.nl.

About Invitrogen

Invitrogen Corporation (Nasdaq:IVGN) provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery, and commercial bioproduction. Invitrogen offers process development services through its PD-Direct(TM) team. The PD-Direct(TM) services provide access to numerous process development capabilities, ranging from vector construction, to media and cell line optimization, to process characterization and scale-up for manufacturing. Invitrogen brings over a decade of experience in process development and manufacturing for cell culture, viral, microbial, and cell therapy products. Founded in 1987, Invitrogen is headquartered in Carlsbad, California, and conducts business in more than 70 countries around the world. The company globally employs approximately 4,800 professionals and had revenues of more than $1.2 billion in 2005. For more information, visit www.invitrogen.com.